The notices it replaced
- Reissues: RFA-NS-24-019 HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
- 2 steps back: RFA-NS-21-010 HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
- 3 steps back: RFA-NS-19-010 Optimization of Non-addictive Therapies [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Not Allowed)
Who won it before
17 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $32,913,121 in first-year total cost, median $2,033,135.
Most frequent study sections
- Special Emphasis Panel[ZNS1 SRB-G (37)]3
- Special Emphasis Panel[ZNS1 SRB-E (05)]2
- Special Emphasis Panel[ZNS1 SRB-G (45)]2
- Special Emphasis Panel[ZNS1 SRB-G (51)]2
- Special Emphasis Panel[ZNS1 SRB-G (55)]2
Most frequent institutions
- CENTREXION THERAPEUTICS CORPORATION1
- CLEVELAND CLINIC LERNER COM-CWRU1
- FZATA, INC.1
- HILLHURST BIOPHARMACEUTICALS, INC.1
- IHP THERAPEUTICS, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Development of MMP-9 inhibitory monoclonal antibodies to relieve neuropathic pain1UG3NS143650-01 · under RFA-NS-24-019 | GE, XINJI, RU-RONG | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $2,079,796 | ZNS1 |
| 2024 | A novel oral immunotherapy for chronic visceral pain of irritable bowel syndrome1UG3NS135350-01A1 · under RFA-NS-21-010 | FENG, HANPINGWEI, FENGYANG, ZHIYONG | FZATA, INC., MD | $2,091,549 | ZNS1 |
| 2023 | Peripherally-restricted non-addictive cannabinoids for cancer pain treatment1UG3NS128148-01A1 · under RFA-NS-21-010 | CAHILL, CATHERINE MSCHMIDT, BRIAN LSPIGELMAN, IGORSPOKOYNY, ALEXANDER MICHAELWHITELEGGE, JULIAN P | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $3,174,343 | ZNS1 |
| 2023 | A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell disease1UG3NS134781-01 · under RFA-NS-21-010 | JOHN PADERI, JOHN PADERI JOHN PADERI | IHP THERAPEUTICS, INC., CA | $2,589,070 | ZNS1 |
| 2023 | Development of positive TMEM97 modulators for treating neuropathic pain1UG3NS131304-01 · under RFA-NS-21-010 | MARTIN, STEPHEN | NUVONURO INC, TX | $1,352,240 | ZNS1 |
| 2023 | Anesthetic-Eluting Contact Lens for Corneal Pain1UG3NS131518-01 · under RFA-NS-21-010 | CIOLINO, JOSEPH B. | SCHEPENS EYE RESEARCH INSTITUTE, MA | $1,120,889 | ZNS1 |
| 2022 | Allosteric Targeting of Cannabinoid CB1 Receptor to Develop Non-Addictive Small Molecule Analgesics1UG3NS128439-01 · under RFA-NS-21-010 | LU, DAISELLEY, DANA ETAO, FENG | TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR, TX | $2,903,097 | ZNS1 |
| 2022 | Development of Pathology-activated Drugs for Treatment of Neuropathic Pain1UG3NS127251-01A1 · under RFA-NS-21-010 | ABELL, ANDREWGRACE, PETER M | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $2,408,109 | ZNS1 |
| 2022 | Oral N2O Therapy in Treating Acute Vaso-Occlusive Pain in Sickle Cell Disease1UG3NS127943-01 · under RFA-NS-21-010 | BELCHER, JOHN DGOMPERTS, EDWARDSIMONE, DONALD | HILLHURST BIOPHARMACEUTICALS, INC., CA | $2,111,258 | ZNS1 |
| 2022 | A first in class, mechanism-guided, cell-based therapy for complex regional pain syndrome1UG3NS127258-01A1 · under RFA-NS-21-010 | CHENG, JIANGUO | CLEVELAND CLINIC LERNER COM-CWRU, OH | $2,033,135 | ZNS1 |
| 2021 | Novel, Non-Opioid, Non-Addictive Intrathecal Therapy for the Treatment of Chronic Pain1UG3NS123965-01 · under RFA-NS-21-010 | CAMPBELL, JAMES N | CENTREXION THERAPEUTICS CORPORATION, MA | $2,050,367 | ZNS1 |
| 2021 | Disease Modifying Analgesia with CA8 Gene Therapy1UG3NS123964-01 · under RFA-NS-21-010 | LEVITT, ROY C. | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $1,516,241 | ZNS1 |
| 2021 | Development of a CCKBR-targeting scFv as Therapy for Chronic Pain Patients1UG3NS123958-01 · under RFA-NS-21-010 | ALLES, SASCHA RWESTLUND-HIGH, KARIN N. | UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR, NM | $999,105 | ZNS1 |
| 2019 | Novel HCN1-selective small molecule inhibitors for the treatment of neuropathic pain1UG3NS114947-01 · under RFA-NS-19-010 | GOLDSTEIN, PETER A | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $1,757,406 | ZNS1 |
| 2019 | Novel mGlu5 negative allosteric modulators as first-in-class non-addictive analgesic therapeutics1UG3NS116218-01 · under RFA-NS-19-010 | CONN, P JEFFREYGEREAU, ROBERT WLINDSLEY, CRAIGROOK, JERRI MICHELLE | VANDERBILT UNIVERSITY, TN | $1,585,635 | ZNS1 |
| 2019 | Development of MRGPRX1 positive allosteric modulators as non-addictive therapies for neuropathic pain1UG3NS115718-01 · under RFA-NS-19-010 | TSUKAMOTO, TAKASHI | JOHNS HOPKINS UNIVERSITY, MD | $1,583,144 | ZNS1 |
| 2019 | Optimization of non-addictive biologics to target sodium channels involved in pain signaling1UG3NS114956-01 · under RFA-NS-19-010 | WULFF, HEIKEYAROV-YAROVOY, VLADIMIR M | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $1,557,737 | ZNS1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-11-0.1.2. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.